fintopic.
Docs Get the API

Biocon clears patent hurdle for breast cancer biosimilar Pebrilzo

3 statements from 3 sources on Nov 16, 2026, 04:18–13:10 UTC
News
Updated
Front page

Statements (3)

  1. Bullish

    Biocon secures U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay) Injection, a biosimilar to Perjeta®.

    businesswire.comHigh importance
  2. Bullish

    Biocon shares gain after US FDA approves cancer drug biosimilar

    cnbctv18.comHigh importance
  3. Bullish

    Biocon received USFDA approval for Pebrilzo, its fifth cancer biosimilar

    business-standard.comHigh importance